Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine.
Animals
Dopamine
/ pharmacology
Glutamic Acid
/ metabolism
Male
Mice
Mice, Knockout
Prefrontal Cortex
/ drug effects
Racemases and Epimerases
/ deficiency
Receptors, Dopamine
/ metabolism
Receptors, N-Methyl-D-Aspartate
/ metabolism
Schizophrenia
Serine
/ metabolism
Synaptic Transmission
/ drug effects
D1- and D2-type receptors
NMDA receptors
d-serine
schizophrenia
serine racemase knockout mice
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
08 06 2021
08 06 2021
Historique:
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Prefrontal control of cognitive functions critically depends upon glutamatergic transmission and N-methyl D-aspartate (NMDA) receptors, the activity of which is regulated by dopamine. Yet whether the NMDA receptor coagonist d-serine is implicated in the dopamine-glutamate dialogue in the prefrontal cortex (PFC) and other brain areas remains unexplored. Here, using electrophysiological recordings, we show that d-serine is required for the fine-tuning of glutamatergic neurotransmission, neuronal excitability, and synaptic plasticity in the PFC through the actions of dopamine at D
Identifiants
pubmed: 34083436
pii: 2023750118
doi: 10.1073/pnas.2023750118
pmc: PMC8201892
pii:
doi:
Substances chimiques
Receptors, Dopamine
0
Receptors, N-Methyl-D-Aspartate
0
Glutamic Acid
3KX376GY7L
Serine
452VLY9402
Racemases and Epimerases
EC 5.1.-
serine racemase
EC 5.1.1.16
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
Competing interest statement: M.J.M. and J.-M.R., respectively, were and are full-time employees of Institut de Recherche Servier and have no other interests to declare. S. Schmidt and J.K. are employees of Pronexus Analytical AB but declare no conflicts of interests.
Références
Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20736-20742
pubmed: 31548413
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16366-71
pubmed: 20805489
Br J Pharmacol. 2012 Mar;165(5):1543-55
pubmed: 21880034
Biol Psychiatry. 2007 May 15;61(10):1200-3
pubmed: 17067558
Neurochem Int. 2019 Sep;128:127-134
pubmed: 30998952
Neuron. 2012 Oct 4;76(1):33-50
pubmed: 23040805
Prog Neurobiol. 2004 Sep;74(1):1-58
pubmed: 15381316
Cereb Cortex. 2001 May;11(5):452-62
pubmed: 11313297
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):E2400-9
pubmed: 23729812
Front Synaptic Neurosci. 2014 May 30;6:12
pubmed: 24910611
Cereb Cortex. 2012 Mar;22(3):595-606
pubmed: 21690263
Curr Pharm Des. 2013;19(14):2499-511
pubmed: 23116391
JAMA Psychiatry. 2013 Dec;70(12):1267-75
pubmed: 24089054
J Neurosci. 2004 Nov 24;24(47):10652-9
pubmed: 15564581
Eur J Pharmacol. 1997 Oct 8;336(2-3):107-12
pubmed: 9384221
Neurosci Lett. 2014 Oct 17;582:93-8
pubmed: 25218715
J Neurosci. 2007 Oct 24;27(43):11496-500
pubmed: 17959792
Neuroscience. 1999;91(2):527-35
pubmed: 10366010
Cell. 2012 Aug 3;150(3):633-46
pubmed: 22863013
Nat Rev Neurosci. 2013 Jun;14(6):383-400
pubmed: 23686171
Brain. 2013 Apr;136(Pt 4):1216-30
pubmed: 23518710
Annu Rev Neurosci. 2009;32:267-87
pubmed: 19555290
Mol Psychiatry. 2009 Jul;14(7):719-27
pubmed: 19065142
Int J Neuropsychopharmacol. 2010 Sep;13(8):1035-51
pubmed: 20663270
J Neurosci. 2017 Jun 14;37(24):5846-5860
pubmed: 28522735
Neuropharmacology. 2013 Nov;74:41-7
pubmed: 23665343
Biol Psychiatry. 2005 Mar 15;57(6):577-85
pubmed: 15780844
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3236-41
pubmed: 14981263
Mol Psychiatry. 2016 Mar;21(3):386-93
pubmed: 26008737
Mol Neurobiol. 2020 May;57(5):2144-2166
pubmed: 31960362
Neuron. 1996 Oct;17(4):789-97
pubmed: 8893035
Biol Psychiatry. 2011 Jun 15;69(12):e113-25
pubmed: 21531388
Biol Psychiatry. 1998 Dec 1;44(11):1081-9
pubmed: 9836012
Cell Mol Neurobiol. 2020 May 22;:
pubmed: 32445040
Int J Neuropsychopharmacol. 2013 Jul;16(6):1395-406
pubmed: 23298512
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E204-13
pubmed: 25550512
J Neurosci. 2000 Nov 15;20(22):RC106
pubmed: 11069975
Synapse. 2004 Oct;54(1):1-10
pubmed: 15300879
J Neurosci. 1997 Nov 15;17(22):8687-94
pubmed: 9348337
CNS Spectr. 2020 Jun;25(3):343-351
pubmed: 31010452
Annu Rev Neurosci. 2001;24:167-202
pubmed: 11283309
J Neurosci. 2004 Jun 2;24(22):5131-9
pubmed: 15175382
Neuroscience. 2006 Apr 28;139(1):263-76
pubmed: 16310964
Neuropsychopharmacology. 2012 Feb;37(3):770-86
pubmed: 22030711
Mol Psychiatry. 2010 Feb;15(2):122-37
pubmed: 19786963
Cereb Cortex. 2009 Apr;19(4):849-60
pubmed: 18689859
Pharmacol Ther. 2016 Sep;165:164-77
pubmed: 27343365
J Pharmacol Exp Ther. 1996 May;277(2):578-85
pubmed: 8627534
J Neurosci Methods. 2011 Nov 15;202(2):143-57
pubmed: 21920385
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):18005-10
pubmed: 24127604
J Neurochem. 2008 Sep;106(6):2489-501
pubmed: 18673451
Eur Neuropsychopharmacol. 2008 Mar;18(3):200-14
pubmed: 17681761